LSTA Stock Price, Chart, Stats & News
Lisata Therapeutics, Inc. (LSTA) does not currently pay a dividend.
LSTA chart
Fundamentals
Gross margin | 91.18% |
Operating margin | -10711.18% |
Pretax margin | -10322.35% |
Net margin | -9756.47% |
Effective tax rate | 5.48% |
ROA | -93.47% |
ROE | -84.39% |
D/E | – |
Interest coverage ratio | – |
LSTA valuation
P/E | – |
P/S | 266.72x |
P/B | 2.94x |
P/CF | -2.73x |
P/FCF | -2.83x |
P/OCF | -2.73x |
PEG | -0.25x |
EV multiple | -3.47x |
About
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis.
Similar securities
Based on sector and market capitalization
